Wall Street brokerages forecast that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will announce earnings of ($0.90) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Alder Biopharmaceuticals’ earnings. The lowest EPS estimate is ($1.38) and the highest is ($0.60). Alder Biopharmaceuticals reported earnings per share of ($0.91) in the same quarter last year, which would suggest a positive year over year growth rate of 1.1%. The business is expected to issue its next earnings report on Monday, November 4th.
On average, analysts expect that Alder Biopharmaceuticals will report full-year earnings of ($4.13) per share for the current fiscal year, with EPS estimates ranging from ($5.76) to ($3.32). For the next year, analysts expect that the company will post earnings of ($2.98) per share, with EPS estimates ranging from ($4.63) to ($1.45). Zacks’ EPS averages are a mean average based on a survey of analysts that cover Alder Biopharmaceuticals.
Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.99) by $0.27.
Several research firms have recently issued reports on ALDR. Svb Leerink began coverage on Alder Biopharmaceuticals in a report on Tuesday, May 28th. They set an “outperform” rating on the stock. Zacks Investment Research upgraded Alder Biopharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $11.00 target price for the company in a research note on Friday, August 9th. Leerink Swann started coverage on Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They issued an “outperform” rating and a $21.00 target price for the company. BidaskClub downgraded Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 3rd. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Alder Biopharmaceuticals in a research note on Wednesday, July 10th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Alder Biopharmaceuticals presently has an average rating of “Buy” and a consensus price target of $16.88.
Shares of ALDR opened at $8.63 on Tuesday. Alder Biopharmaceuticals has a fifty-two week low of $8.39 and a fifty-two week high of $18.95. The company has a market capitalization of $715.12 million, a PE ratio of -1.77 and a beta of 2.56. The stock has a fifty day moving average of $9.43 and a two-hundred day moving average of $11.56. The company has a debt-to-equity ratio of 1.74, a quick ratio of 8.94 and a current ratio of 8.94.
Institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its position in Alder Biopharmaceuticals by 22.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock worth $11,910,000 after purchasing an additional 215,098 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Alder Biopharmaceuticals by 10.3% during the first quarter. Rhumbline Advisers now owns 107,797 shares of the biopharmaceutical company’s stock worth $1,471,000 after buying an additional 10,035 shares in the last quarter. TD Asset Management Inc. grew its holdings in shares of Alder Biopharmaceuticals by 4.2% during the first quarter. TD Asset Management Inc. now owns 220,064 shares of the biopharmaceutical company’s stock worth $3,004,000 after buying an additional 8,881 shares in the last quarter. Fosun International Ltd raised its position in shares of Alder Biopharmaceuticals by 26.5% in the first quarter. Fosun International Ltd now owns 233,858 shares of the biopharmaceutical company’s stock valued at $3,113,000 after buying an additional 49,045 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in shares of Alder Biopharmaceuticals by 22.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biopharmaceutical company’s stock valued at $432,000 after buying an additional 4,400 shares during the last quarter.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Further Reading: What is Cost of Goods Sold (COGS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.